Bristol Myers Squibb (NYSE:BMY) Director Julia Haller Sells 3,800 Shares of Company Stock

Key Points

• Director Julia Haller sold 3,800 Bristol Myers Squibb shares at an average price of $63.31, totaling about $240,578; she retained 30,279 shares after the sale.
• The company beat quarterly estimates, reporting EPS of $1.35 versus $1.10 expected and revenue of $13.07 billion, up 6.9% year over year. Shares fell 1.5% in Friday trading to $62.20.
• Bristol Myers Squibb’s quarterly dividend is $0.63 per share, equivalent to an annualized $2.52 and a yield of about 4.1%; analysts’ average rating is “Hold,” with a $65.46 average price target.

Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) Director Julia Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares of the company's stock, valued at $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bristol Myers Squibb Trading Down 1.5%

NYSE:BMY traded down $0.93 during mid-day trading on Friday, hitting $62.20. 9,094,785 shares of the stock traded hands, compared to its average volume of 12,013,368. Bristol Myers Squibb Company has a 52 week low of $45.26 and a 52 week high of $68.64. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. The stock has a market capitalization of $127.15 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 0.33 and a beta of 0.20. The firm's 50 day moving average is $62.44 and its two-hundred day moving average is $60.07.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.25. The firm had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb's quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.63 earnings per share. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.88%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BMY. Wells Fargo & Company dropped their target price on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating for the company in a report on Tuesday, October 13th. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Bank of America reiterated a "buy" rating on shares of Bristol Myers Squibb in a research note on Friday, October 30th. Finally, Zacks Research lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb presently has an average rating of "Hold" and an average target price of $65.46.

Institutional Trading of Bristol Myers Squibb

A number of large investors have recently made changes to their positions in BMY. BlackRock Inc. boosted its holdings in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. State Street Corp raised its holdings in Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Bristol Myers Squibb by 0.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company's stock worth $1,315,984,000 after acquiring an additional 119,690 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Bristol Myers Squibb by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company's stock worth $1,137,847,000 after buying an additional 520,330 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.